Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Dr Denis Lacombe, CEO of EORTC, has been appointed as the stakeholder co-chair of the ACT EU advisory group for a two-year mandate. This role offers new opportunities to collaborate more closely with regulatory bodies and other stakeholders, addressing daily challenges and developing new opportunities for conducting clinical research in Europe.
Additionally, Stephanie Kromar, Head of the Regulatory Department, and Stephane Lejeune, Head of the International Affairs and Policies Department, will represent EORTC on the ACT EU Advisory Group.
ACT EU is a unique initiative aimed at optimising the conduct of clinical research in Europe by addressing challenges arising from the rapidly evolving regulatory ecosystem and developing a specific scheme for academic clinical research.
ACT EU’s mission is to transform the initiation, design, and execution of clinical trials, promoting the development of high-quality, safe, and effective medicines. It also seeks to better integrate clinical research within the European health system. For more detailed information, visit Accelerating Clinical Trials in the EU (ACT EU) | European Medicines Agency (europa.eu).
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023